Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Hello, "Without a revenue stream or a commercial release date for initial products and services, there is no way to estimate future cash requirements."
100% correct. About the only thing we know about "future cash requirements" is that they will more and more of it not only for current trials but also a couple of new trials slated for 2023.

"Is the published data from Baylor and MarkerT, in fact, reliable?"
Although without me being divine, so can never be positive, I would have to answer Yes to that.

"If the data is reliable and the underlying technology is sound, is it sufficiently differentiated from their competition [genetic engineering, 'fast' & scalable manufacturing, perhaps lower cost] to provide competitive advantage?
That would be another 100% correct. I believe it is WAY MORE than sufficiently differentiated.
10 times cheaper, 10 times faster, NO Cytokine Release Syndrome reported at all (CAR-T does and has killed patients), the Big Advantage of Epitope Spreading, Disease targeted antigens, has shown good success even in the "active" (worse) group, etc..

But Please, don't listen to me, I'm already down about 125k in MRKR.